FDA lifts partial hold on Merck, Daiichi's Phase 3 lung cancer study

The FDA on Monday lifted a partial clinical hold on a Phase 3 lung cancer study run by Merck and Daiichi Sankyo. Regulators had placed the hold just last month after seeing ...